EZZ Life Science Holdings Ltd. (AU:EZZ)
ASX:EZZ
EZZ Stock Chart & Stats
AU$1.45
-AU$0.25(-8.71%)
At close: 4:00 PM EST
AU$1.45
-AU$0.25(-8.71%)
Day’s Range― - ―
52-Week RangeAU$0.83 - AU$3.38
Previous CloseN/A
Volume93.44K
Average Volume (3M)49.70K
Market Cap
AU$41.40M
Enterprise ValueAU$28.05M
Total Cash (Recent Filing)AU$13.47M
Total Debt (Recent Filing)AU$123.86K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.81%
Share Statistics
EPS (TTM)-0.01
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.57
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained gross margins above 70% and ~10% net margin indicate durable unit economics and pricing power in nutraceuticals. This margin buffer supports reinvestment in product development, marketing, and preserves profitability during demand swings over the next several quarters.
Low Leverage / Strong Balance SheetA very low debt-to-equity profile and solid equity financing provide long-term financial flexibility, reducing solvency risk. This balance sheet strength allows the company to fund working capital, pursue growth initiatives or weather revenue volatility without urgent external financing.
Efficient Operations And Healthy MarginsConsistently healthy EBIT/EBITDA margins reflect operational efficiency and cost control across manufacturing and distribution. This efficiency supports margin sustainability even if top-line growth stalls, preserving free cash generation potential over a multi-quarter horizon.
Bears Say
Declining And Volatile RevenueRecent material revenue decline and volatility reduce visibility into growth trajectory and raise questions about market demand or distribution execution. Sustained top-line weakness can constrain scale benefits, R&D spending, and long-term expansion into Asian cross-border channels.
Weaker Cash ConversionOperating cash conversion below one and falling free cash flow growth signal difficulty turning accounting profits into liquidity. Over months, this can limit self-funding of inventory and marketing, increase reliance on external funding, and pressure flexibility during business slowdowns.
Sharp EPS DeteriorationA roughly 70% decline in EPS reflects significant earnings volatility or one-off hits, undermining confidence in sustained profitability. Large EPS swings reduce retained earnings growth and can constrain dividend or reinvestment policies, affecting long-term shareholder returns.
EZZ Life Science Holdings Ltd. News
EZZ FAQ
What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?
EZZ Life Science Holdings Ltd. lowest share price was AU$0.83 and its highest was AU$3.38 in the past 12 months.
What is EZZ Life Science Holdings Ltd.’s market cap?
EZZ Life Science Holdings Ltd.’s market cap is AU$41.40M.
When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?
EZZ Life Science Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 157 days.
How were EZZ Life Science Holdings Ltd.’s earnings last quarter?
EZZ Life Science Holdings Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is EZZ Life Science Holdings Ltd. overvalued?
According to Wall Street analysts EZZ Life Science Holdings Ltd.’s price is currently Overvalued.
Does EZZ Life Science Holdings Ltd. pay dividends?
EZZ Life Science Holdings Ltd. pays a Semiannually dividend of AU$0.02 which represents an annual dividend yield of 2.81%. See more information on EZZ Life Science Holdings Ltd. dividends here
What is EZZ Life Science Holdings Ltd.’s EPS estimate?
EZZ Life Science Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EZZ Life Science Holdings Ltd. have?
EZZ Life Science Holdings Ltd. has 47,043,200 shares outstanding.
What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?
EZZ Life Science Holdings Ltd. reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.326%.
Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:EZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EZZ Life Science Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EZZ Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
10.35%
Trailing 12-Months
Asset Growth
9.62%
Trailing 12-Months
Company Description
EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as grocery retailers. The company also designs, develops, produces, distributes, and sells consumer health products, including vitamins and dietary supplements, sports nutrition, weight management and wellbeing, herbal/traditional, and paediatric products under the EZZ brand through its e-commerce platforms and stores, such as Tmall Global. EZZ Life Science Holdings Limited was incorporated in 2015 and is based in Silverwater, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---